The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Charles River Laboratories International Inc

NYSE: CRL
Last

(U.S.) $114.58

Today's change+0.34 +0.30%
Updated October 18 11:16 AM EDT. Delayed by at least 15 minutes.
 

Charles River Laboratories International Inc

NYSE: CRL
Last

(U.S.) $114.58

Today's change+0.34 +0.30%
Updated October 18 11:16 AM EDT. Delayed by at least 15 minutes.

Charles River Laboratories International Inc Hits New 100-day High

Charles River Laboratories International Inc is up today by (U.S.)$0.34 or 0.30% to (U.S.)$114.58 and setting a new 100-day high. Over the last five days, shares have gained 1.57% and 50.38% year to date. Shares have outperformed the S&P 500 by 21.64% during the last year.

Key company metrics

  • Open(U.S.) $114.58
  • Previous close(U.S.) $114.23
  • High(U.S.) $114.91
  • Low(U.S.) $114.01
  • Bid / Ask(U.S.) $114.40 / (U.S.) $114.75
  • YTD % change+50.38%
  • Volume111,798
  • Average volume (10-day)270,609
  • Average volume (1-month)361,448
  • Average volume (3-month)340,079
  • 52-week range(U.S.) $67.20 to (U.S.) $114.91
  • Beta0.93
  • Trailing P/E30.25×
  • P/E 1 year forward22.41×
  • Forward PEG2.06×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $3.79
Updated October 18 11:16 AM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+10.21%

Based on its net profit margin of 10.21%, Charles River Laboratories International Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.04%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJul 01, 201707/01/2017Apr 01, 201704/01/2017Dec 31, 201612/31/2016Sep 24, 201609/24/2016
Revenue469446467426
Total other revenue--------
Total revenue469446467426
Gross profit186172180156
Total cost of revenue283274287269
Total operating expense388376398367
Selling / general / administrative94919483
Research & development--------
Depreciation / amortization10111212
Interest expense (income), net operating--------
Unusual expense (income)1143
Other operating expenses, total--------
Operating income81696959
Interest income (expense), net non-operating-7-7-8-7
Gain (loss) on sale of assets--------
Other--------
Income before tax77786453
Income after tax55474538
Income tax, total22311816
Net income54474538
Total adjustments to net income--------
Net income before extra. items54474537
Minority interest-10-10
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items54474537
Inc. avail. to common incl. extra. items54474538
Diluted net income54474538
Dilution adjustment0------
Diluted weighted average shares48484848
Diluted EPS excluding extraordinary itemsvalue per share1.120.970.930.78
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share1.140.991.060.94